Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 10Wilms Tumor 9Leukemia, Myeloid, Acute 9Osteosarcoma 8Neuroblastoma 8Neoplasm Metastasis 8Multiple Myeloma 8Lung Neoplasms 8Glioma 8Sarcoma 7Rhabdoid Tumor 7Lymphoma, Non-Hodgkin 7Hepatoblastoma 7Carcinoma, Hepatocellular 7Rhabdomyosarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Myelodysplastic Syndromes 6Medulloblastoma 6Lymphoma 6Histiocytosis, Langerhans-Cell 6Ependymoma 6Colorectal Neoplasms 6Breast Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Melanoma 5Central Nervous System Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Sarcoma, Ewing 4Ovarian Neoplasms 4Endometrial Neoplasms 4

Interventions

luprolide acetate gel depot 1exemestane 1darolutamide 1X-Rays 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Leuprolide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Granulosa cell tumor of the ovary × X-Rays × 90 days × Clear all
NCT06169124 2026-05-13

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
37 enrolled

Granulosa cell tumor of the ovary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡